Moderna (MRNA) Issues Statement on IP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Moderna (MRNA) Issues Statement on IP

Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program

November 15, 2021 5:22 AM EST

Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim data from an ongoing Phase 1 clinical study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas. The data showed that the Companys mRNA Triplet program given in combination with AstraZenecas durvalumab (IMFINZI®) was tolerated at all dose levels tested and elicited evidence of anti-tumor activity. The recommended dose for expansion (RDE) is up to of 8mg mRNA-2752 + durvalumab.

We are encouraged by the interim data from our Triplet program, which combines three... More